Please use this identifier to cite or link to this item: http://cuir.car.chula.ac.th/handle/123456789/61885
Title: Risk profiles and pattern of antithrombotic use in patients with non-valvular atrial fibrillation in Thailand : a multicenter study
Authors: Rungroj Krittayaphong
Arjbordin Winijkul
Komsing Methavigul
Wattana Wongtheptien
Chaiyasith Wongvipaporn
Treechada Wisaratapong
Rapeephon Kunjara-Na-Ayudhya
Smonporn Boonyaratvej
Chulalak Komoltri
Pontawee Kaewcomdee
Ahthit Yindeengam
Piyamitr Sritara
Email: No information provided
No information provided
No information provided
No information provided
No information provided
No information provided
No information provided
No information provided
No information provided
No information provided
No information provided
No information provided
Other author: Chulalongkorn University. Faculty of Medicine
Issue Date: 25-Aug-2018
Publisher: BioMed Central Ltd.
Citation: BMC Cardiovascular Disorders. Vol.18, Article No. 174 (2018), 6 pages
Abstract: Background : Anticoagulation therapy is a standard treatment for stroke prevention in patients with non-valvular atrial fibrillation (NVAF) that have risk factors for stroke. However, anticoagulant increases the risk of bleeding, especially in Asians. We aimed to investigate the risk profiles and pattern of antithrombotic use in patients with NVAF in Thailand, and to study the reasons for not using warfarin in this patient population. Methods : A nationwide multicenter registry of patients with NVAF was created that included data from 24 hospitals located across Thailand. Demographic data, atrial fibrillation-related data, comorbid conditions, use of antithrombotic drugs, and reasons for not using warfarin were collected. Data were recorded in a case record form and then transferred into a web-based system. Results : A total of 3218 patients were included. Average age was 67.3 ± 11.3 years, and 58.2% were male. Average CHADS2, CHA2DS2-VASc, and HAS-BLED score was 1.8 ± 1.3, 3.0 ± 1.7, and 1.5 ± 1.0, respectively. Antiplatelet was used in 26.5% of patients, whereas anticoagulant was used in 75.3%. The main reasons for not using warfarin in those with CHA2DS2-VASc ≥2 included already taking antiplatelet (26.6%), patient preference (23.1%), and using non-vitamin K antagonist oral anticoagulants (NOACs) (22.7%). Anticoagulant was used in 32.3% of CHA2DS2-VASc 0, 56.8% of CHA2DS2-VASc 1, and 81.6% of CHA2DS2-VASc ≥2. The use of NOACs increased from 1.9% in 2014 to 25.6% in 2017. Conclusions : Anticoagulation therapy was prescribed in 75.3% of patients with NVAF. Among those receiving anticoagulant, 90.9% used warfarin and 9.1% used NOACs. The use of NOACs increased over time.
URI: http://cuir.car.chula.ac.th/handle/123456789/61885
URI: https://doi.org/10.1186/s12872-018-0911-4
https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/s12872-018-0911-4
ISSN: 1471-2261
metadata.dc.identifier.DOI: 10.1186/s12872-018-0911-4
Type: Article
Appears in Collections:Chula Scholars - 2018

Files in This Item:
File Description SizeFormat 
html_submission_64777.htmlLink to Fulltext2.86 kBHTMLView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.